23.99 USD
+0.01 (+0.04%)
23.99 USD
0 (0%)
Overall PCRX gets a fundamental rating of 6 out of 10. We evaluated PCRX against 192 industry peers in the Pharmaceuticals industry. While PCRX belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health. PCRX has a bad growth rate and is valued cheaply. These ratings could make PCRX a good candidate for value investing.
1. Profitability
1.1 Basic Checks
In the past year PCRX was profitable.
PCRX had a positive operating cash flow in the past year.
PCRX had positive earnings in 4 of the past 5 years.
PCRX had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
The Return On Assets of PCRX (1.65%) is better than 82.29% of its industry peers.
PCRX's Return On Equity of 2.95% is amongst the best of the industry. PCRX outperforms 83.33% of its industry peers.
Looking at the Return On Invested Capital, with a value of 3.63%, PCRX belongs to the top of the industry, outperforming 81.77% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for PCRX is significantly below the industry average of 12.71%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.65% | ||
| ROE | 2.95% | ||
| ROIC | 3.63% |
ROA(3y)-0.93%
ROA(5y)2.13%
ROE(3y)-1.97%
ROE(5y)4.66%
ROIC(3y)4.3%
ROIC(5y)4.55%
1.3 Margins
With an excellent Profit Margin value of 2.99%, PCRX belongs to the best of the industry, outperforming 80.21% of the companies in the same industry.
Looking at the Operating Margin, with a value of 8.88%, PCRX belongs to the top of the industry, outperforming 80.73% of the companies in the same industry.
In the last couple of years the Operating Margin of PCRX has grown nicely.
With an excellent Gross Margin value of 79.17%, PCRX belongs to the best of the industry, outperforming 83.33% of the companies in the same industry.
PCRX's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 8.88% | ||
| PM (TTM) | 2.99% | ||
| GM | 79.17% |
OM growth 3Y-15.96%
OM growth 5Y11.41%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.7%
GM growth 5Y0.27%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), PCRX is destroying value.
PCRX has less shares outstanding than it did 1 year ago.
Compared to 5 years ago, PCRX has more shares outstanding
Compared to 1 year ago, PCRX has a worse debt to assets ratio.
2.2 Solvency
PCRX has an Altman-Z score of 2.00. This is not the best score and indicates that PCRX is in the grey zone with still only limited risk for bankruptcy at the moment.
PCRX has a Altman-Z score (2.00) which is comparable to the rest of the industry.
PCRX has a debt to FCF ratio of 3.03. This is a good value and a sign of high solvency as PCRX would need 3.03 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 3.03, PCRX belongs to the top of the industry, outperforming 90.10% of the companies in the same industry.
PCRX has a Debt/Equity ratio of 0.52. This is a neutral value indicating PCRX is somewhat dependend on debt financing.
The Debt to Equity ratio of PCRX (0.52) is worse than 61.98% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.52 | ||
| Debt/FCF | 3.03 | ||
| Altman-Z | 2 |
ROIC/WACC0.47
WACC7.8%
2.3 Liquidity
PCRX has a Current Ratio of 5.26. This indicates that PCRX is financially healthy and has no problem in meeting its short term obligations.
With a decent Current ratio value of 5.26, PCRX is doing good in the industry, outperforming 66.15% of the companies in the same industry.
PCRX has a Quick Ratio of 3.78. This indicates that PCRX is financially healthy and has no problem in meeting its short term obligations.
PCRX has a Quick ratio of 3.78. This is comparable to the rest of the industry: PCRX outperforms 57.81% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.26 | ||
| Quick Ratio | 3.78 |
3. Growth
3.1 Past
PCRX shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -6.90%.
The Earnings Per Share has been growing by 13.96% on average over the past years. This is quite good.
PCRX shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -16.85%.
PCRX shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 10.73% yearly.
EPS 1Y (TTM)-6.9%
EPS 3Y2.39%
EPS 5Y13.96%
EPS Q2Q%-11.39%
Revenue 1Y (TTM)-16.85%
Revenue growth 3Y8.98%
Revenue growth 5Y10.73%
Sales Q2Q%6.49%
3.2 Future
The Earnings Per Share is expected to grow by 7.17% on average over the next years.
PCRX is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 6.09% yearly.
EPS Next Y-8.75%
EPS Next 2Y1.59%
EPS Next 3Y6.02%
EPS Next 5Y7.17%
Revenue Next Year5.37%
Revenue Next 2Y7.75%
Revenue Next 3Y8.09%
Revenue Next 5Y6.09%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 8.08, which indicates a very decent valuation of PCRX.
92.19% of the companies in the same industry are more expensive than PCRX, based on the Price/Earnings ratio.
When comparing the Price/Earnings ratio of PCRX to the average of the S&P500 Index (26.46), we can say PCRX is valued rather cheaply.
Based on the Price/Forward Earnings ratio of 7.24, the valuation of PCRX can be described as very cheap.
Based on the Price/Forward Earnings ratio, PCRX is valued cheaper than 93.75% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 36.10. PCRX is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 8.08 | ||
| Fwd PE | 7.24 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, PCRX is valued cheaply inside the industry as 93.23% of the companies are valued more expensively.
PCRX's Price/Free Cash Flow ratio is rather cheap when compared to the industry. PCRX is cheaper than 91.15% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 8.31 | ||
| EV/EBITDA | 6.88 |
4.3 Compensation for Growth
PCRX has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.58
EPS Next 2Y1.59%
EPS Next 3Y6.02%
5. Dividend
5.1 Amount
PCRX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
23.99
+0.01 (+0.04%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners114.07%
Inst Owner Change-5.56%
Ins Owners0.79%
Ins Owner Change-0.27%
Market Cap1.03B
Revenue(TTM)716.79M
Net Income(TTM)21.44M
Analysts76.92
Price Target30.77 (28.26%)
Short Float %17.24%
Short Ratio11.78
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)3.71%
Min EPS beat(2)2.13%
Max EPS beat(2)5.28%
EPS beat(4)4
Avg EPS beat(4)4.05%
Min EPS beat(4)1.99%
Max EPS beat(4)6.81%
EPS beat(8)6
Avg EPS beat(8)5.89%
EPS beat(12)7
Avg EPS beat(12)1.4%
EPS beat(16)8
Avg EPS beat(16)-3.85%
Revenue beat(2)0
Avg Revenue beat(2)-3.29%
Min Revenue beat(2)-3.59%
Max Revenue beat(2)-2.99%
Revenue beat(4)0
Avg Revenue beat(4)-3.23%
Min Revenue beat(4)-5.92%
Max Revenue beat(4)-0.42%
Revenue beat(8)1
Avg Revenue beat(8)-2.14%
Revenue beat(12)1
Avg Revenue beat(12)-2.68%
Revenue beat(16)1
Avg Revenue beat(16)-2.53%
PT rev (1m)-1.07%
PT rev (3m)-1.07%
EPS NQ rev (1m)4.68%
EPS NQ rev (3m)5.08%
EPS NY rev (1m)0.7%
EPS NY rev (3m)1.33%
Revenue NQ rev (1m)-1.94%
Revenue NQ rev (3m)-2.09%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.08%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 8.08 | ||
| Fwd PE | 7.24 | ||
| P/S | 1.44 | ||
| P/FCF | 8.31 | ||
| P/OCF | 7.3 | ||
| P/B | 1.42 | ||
| P/tB | 3.18 | ||
| EV/EBITDA | 6.88 |
EPS(TTM)2.97
EY12.38%
EPS(NY)3.31
Fwd EY13.81%
FCF(TTM)2.89
FCFY12.03%
OCF(TTM)3.29
OCFY13.7%
SpS16.66
BVpS16.9
TBVpS7.54
PEG (NY)N/A
PEG (5Y)0.58
Graham Number33.61
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.65% | ||
| ROE | 2.95% | ||
| ROCE | 5.34% | ||
| ROIC | 3.63% | ||
| ROICexc | 4.58% | ||
| ROICexgc | 7.99% | ||
| OM | 8.88% | ||
| PM (TTM) | 2.99% | ||
| GM | 79.17% | ||
| FCFM | 17.33% |
ROA(3y)-0.93%
ROA(5y)2.13%
ROE(3y)-1.97%
ROE(5y)4.66%
ROIC(3y)4.3%
ROIC(5y)4.55%
ROICexc(3y)6.05%
ROICexc(5y)7.29%
ROICexgc(3y)13.64%
ROICexgc(5y)24.93%
ROCE(3y)6.32%
ROCE(5y)6.69%
ROICexgc growth 3Y-33.29%
ROICexgc growth 5Y14.33%
ROICexc growth 3Y-3.13%
ROICexc growth 5Y10.2%
OM growth 3Y-15.96%
OM growth 5Y11.41%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.7%
GM growth 5Y0.27%
F-Score7
Asset Turnover0.55
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.52 | ||
| Debt/FCF | 3.03 | ||
| Debt/EBITDA | 2.44 | ||
| Cap/Depr | 18.95% | ||
| Cap/Sales | 2.4% | ||
| Interest Coverage | 4.07 | ||
| Cash Conversion | 91.52% | ||
| Profit Quality | 579.36% | ||
| Current Ratio | 5.26 | ||
| Quick Ratio | 3.78 | ||
| Altman-Z | 2 |
F-Score7
WACC7.8%
ROIC/WACC0.47
Cap/Depr(3y)22.15%
Cap/Depr(5y)83.49%
Cap/Sales(3y)2.76%
Cap/Sales(5y)5.11%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-6.9%
EPS 3Y2.39%
EPS 5Y13.96%
EPS Q2Q%-11.39%
EPS Next Y-8.75%
EPS Next 2Y1.59%
EPS Next 3Y6.02%
EPS Next 5Y7.17%
Revenue 1Y (TTM)-16.85%
Revenue growth 3Y8.98%
Revenue growth 5Y10.73%
Sales Q2Q%6.49%
Revenue Next Year5.37%
Revenue Next 2Y7.75%
Revenue Next 3Y8.09%
Revenue Next 5Y6.09%
EBIT growth 1Y-45.68%
EBIT growth 3Y-8.41%
EBIT growth 5Y23.37%
EBIT Next Year0.19%
EBIT Next 3Y7.79%
EBIT Next 5Y6.85%
FCF growth 1Y-4.68%
FCF growth 3Y30.84%
FCF growth 5Y24.28%
OCF growth 1Y-5.2%
OCF growth 3Y14.64%
OCF growth 5Y21.85%
PACIRA BIOSCIENCES INC / PCRX FAQ
What is the ChartMill fundamental rating of PACIRA BIOSCIENCES INC (PCRX) stock?
ChartMill assigns a fundamental rating of 6 / 10 to PCRX.
What is the valuation status of PACIRA BIOSCIENCES INC (PCRX) stock?
ChartMill assigns a valuation rating of 8 / 10 to PACIRA BIOSCIENCES INC (PCRX). This can be considered as Undervalued.
How profitable is PACIRA BIOSCIENCES INC (PCRX) stock?
PACIRA BIOSCIENCES INC (PCRX) has a profitability rating of 7 / 10.
What are the PE and PB ratios of PACIRA BIOSCIENCES INC (PCRX) stock?
The Price/Earnings (PE) ratio for PACIRA BIOSCIENCES INC (PCRX) is 8.08 and the Price/Book (PB) ratio is 1.42.
What is the financial health of PACIRA BIOSCIENCES INC (PCRX) stock?
The financial health rating of PACIRA BIOSCIENCES INC (PCRX) is 6 / 10.